TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04497376

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: upgraded '2C3L'
Description: Patients randomized to the upgraded '2C3L' arm will first undergo EI-VOM, followed by the '2C3L' ablation step. The details include: (1). EI-VOM procedure: An 8.5-French-long sheath or a steerable long sheath is sent to the coronary sinus (CS) via the femoral vein. A JR4.0 catheter is inserted into the CS to identify the ostium of the VOM. Subsequently, a BMW wire supported by an OTW balloon catheter is advanced into the VOM. The balloon is inflated with 6 to 8 atm in the VOM. A selective venogram of the VOM is obtained by slowly injecting 1 mL of contrast medium. Then, ethanol is slowly injected into the VOM and selective venography of the VOM is repeated. (2) . After EI-VOM, radiofrequency ablation was performed to achieve bilateral pulmonary vein isolation and bidirectional block of mitral isthmus line, roof line, and cavotricuspid isthmus line. (3). Any organized AT observed during the procedure will be targeted as well.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulmonary vein antral isolation
Description: After reconstructing the left atrial geometry, PVI will be performed (the right PV antrum (PVA) will be ablated first, followed by the left PVA. ) in a wide area circumferential pattern. Complete PVI will be achieved when all PV potentials within each antrum recorded by the high-density mapping catheter are abolished. The endpoint of the circumferential PVA ablation procedure is to achieve electrical bilateral PV isolation, that is, the PV potentials associated with atrial electrical activity cannot be recorded during sinus rhythm or CS pacing (entrance block). A waiting period of at least 20 min (after the last PV is isolated) will be used during which spontaneous PV reconnection will be related. , and tDemonstration of exit block (he by pacing in the PV cannot be and proving the absence of transmitted conduction to capture the atrium) may be performed but is not mandatory. Any organized AT observed during the procedure will be targeted as well.
Study: NCT05669508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RISES-T System
Description: Non-invasive closed-loop electrical stimulation of the spinal cord through the skin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational/Physical Therapy
Description: Exercise therapy to improve function of upper and/or lower limbs
Study: NCT06322095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1
Description: Previous PD-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MET inhibitor
Description: Previous MET inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALK inhibitor
Description: Previous ALK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRAF Inhibito
Description: Previous BRAF inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR Monoclonal antibody
Description: Previous EGFR Monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH21
Description: Oral, 15mg BIW or 6mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH21
Description: Oral, 15mg BIW or 6mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH21
Description: Oral, 15mg BIW or 6mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH21
Description: Oral, 15mg BIW or 6mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH21
Description: Oral, 15mg BIW or 6mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK Inhibitor
Description: Previous MEK Inhibitor
Study: NCT06319768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: Patients will be treated with intralesional PTX (Trentoximal Ampoule 100 mg/5 ml) in a dose of 1mg per lesion at a distance 1cm between two atrophic lesions with a maximum 20 mg per session (with insulin syringe 30Gx8mm). Lesion blanching is the endpoint of injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma
Description: Patients will be treated with intralesional PRP. PRP will be obtained by the double-spin method, followed by the collection of 10 mL of autologous whole blood into tubes containing trisodium citrate as an anticoagulant. The collected blood will first be centrifuged at 1000 RPM for 10 minutes at room temperature to separate the red blood cells at the bottom of the tube, the buffy coat (containing the white blood cells) in the middle, and the plasma above (soft spin). Then, the upper plasma will be pipetted above the buffy coat to undergo another centrifugation at 1500 RPM for another10 minutes (hard spin) to obtain a platelet pellet in the bottom of the tube (with a platelet count 4-4.5 times higher than that of baseline) and a platelet-poor plasma(PPP) in the upper part. The PPP will be partly removed and partly used to re-suspend the platelets to finally produce 2 mL of PRP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combined pentoxifylline and platelet rich plasma
Description: Patients will be treated with a combination of both intralesional 1mg of PTX per lesion (with a maximum 20mg per session) then 0.1ml of intralesional PRP at the same lesion after 5 minutes
Study: NCT06131996

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volar supported splint
Description: participants used volar supported splint during sleep for 4 weeks. Exercise was performed at home for a total of 12 sessions, three sessions per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: elastic splint
Description: participants used velastic splint during sleep for 4 weeks. Exercise was performed at home for a total of 12 sessions, three sessions per week
Study: NCT05817435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod PH20 SC as a prefilled syringe presentation
Description: efgartigimod PH20 SC as a prefilled syringe presentation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: efgartigimod PH20 SC as a vial + syringe presentation
Description: efgartigimod PH20 SC as a vial + syringe presentation
Study: NCT05730738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalfampridine ER, 10 Mg Oral Tablet, Extended Release
Description: The only approved treatment for impaired ambulation in MS is Dalfampridine (also known as fampridine, 4-aminopyridine, 4-AP). Fampridine penetrates the blood-brain barrier and improves impaired axonal conduction by selectively blocking potassium channels

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo similar to Dalfampridine capsule
Study: NCT05640726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1
Description: Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SCRT
Description: Radiotherapy dose: 5×5 Gy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive bevacizumab，5mg/kg，intravenously over 60 - 90 minutes, day 1 of every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive Oxaliplatin，85mg/m2，day1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium folinate
Description: Participants will receive calcium folinate ，400mg/m2，day1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Participants will receive 5-fluorouracil ，400mg/m2，day1
Study: NCT06114875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support intervention
Description: Flags will appear beside posts that the risk algorithm has identified as containing descriptions of distress or mental health concerns (these flags will not be visible to the original poster). Next to these flags, users will also see a brief blurb such as: This person might be going through something difficult. To learn more about what to say to peers who may be experiencing distress, click this banner. RallyPoint users will then have the option of clicking on these flags, where they will be directed to a psychoeducational information page on how to provide support to peers who may be experiencing distress.
Study: NCT06437821

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Petrissage
Description: The calf muscles will receive a firm, deep-circulation massage with fingertip pressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graston Technique
Description: The calf muscles will receive a firm, deep-circulation massage with fingertip pressure
Study: NCT05680051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon
Description: Drug eluting balloon was used in the experimental group

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent
Description: Drug eluting stent was used in the control group
Study: NCT05197647

Intervention type: OTHER
Intervention: Patients with symptomatic COVID-19 disease not requiring hospitalization.
Description: Patients with symptomatic COVID-19 disease not requiring hospitalization.
Study: NCT05266105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palazestrant
Description: Complete Estrogen Receptor Antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palazestrant
Description: Complete Estrogen Receptor Antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is an approved CDK 4/6 Inhibitor drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is an approved CDK 4/6 Inhibitor drug
Study: NCT05538182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Based on the refraction results, study participants diagnosed with refractive error will be dispensed two free pairs of distance spectacles.
Study: NCT05082142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Patients in the intervention arm will receive 1g of intraoperative IV TXA during the HoLEP procedure.
Study: NCT04717973

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory testing of CBC, serum ferritin, and vitamin B 12
Description: laboratory testing of CBC, serum ferritin, and vitamin B 12, vitamin D and ionized serum calcium after the 1st month, 3rd month, 6th month, and then after one year postoperative.~The pre-operative and post-operative measures will be compared in patients who will be subjected to Laparoscopic Sleeve Gastrectomy versus Laparoscopic Gastric Bypass.

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory testing of CBC, serum ferritin, and vitamin B 12
Description: laboratory testing of CBC, serum ferritin, and vitamin B 12, vitamin D and ionized serum calcium after the 1st month, 3rd month, 6th month, and then after one year postoperative.~The pre-operative and post-operative measures will be compared in patients who will be subjected to Laparoscopic Sleeve Gastrectomy versus Laparoscopic Gastric Bypass.
Study: NCT06019013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLF3108
Description: QLF3108 will be administered independent of body weight.
Study: NCT05885035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxyapatite
Description: Each syringe of CaHA contains 1.5 cc of product, and it will be diluted 1:1 with 1.0 cc of normal saline solution and 0.5 cc of 1% Lidocaine with a ratio of 1:100,000 epinephrine in the target sites.
Study: NCT06320015

Intervention type: BEHAVIORAL
Intervention: Substance Misuse Assistance Response Team (SMART)
Description: The study intervention is engagement with a Substance Misuse Assistance Response Team (SMART) community health worker-peer recovery specialist (PCHW). SMART PCHWs engage ED patients with substance use disorders and facilitates ED services provision and linkages to outpatient care. Services provided include supporting ED initiation of buprenorphine, harm reduction services, social services (transportation, housing assistance, etc.), and engagement in peer recovery, behavioral health services, and addiction treatment services. Services are provided at the time of the ED visit. A subgroup of patients is provided short term case management and outpatient services navigation depending on PCHW caseload availability and individual needs.

Intervention type: OTHER
Intervention: Usual Care Group
Description: Patient not seen by a SMART community health worker in the emergency department. Care and treatment referral at discretion of emergency department treating team.
Study: NCT06419543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Observe the incidence of paradoxical reactions after the first induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Observe the incidence of paradoxical reactions after the first induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Observe the incidence of paradoxical reactions after the first induction.
Study: NCT05814016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danavorexton
Description: Danavorexton IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danavorexton
Description: Danavorexton IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching danavorexton IV infusion.
Study: NCT05897086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol 3350
Description: Topical irrigation with approximately 2 ccs of a 190 mM solution of 50% PEG 3.35 kD in sterile water
Study: NCT05537441

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text messaging
Description: Patients will receive up to 3 text messages reminding them about the importance of influenza vaccination during the 2022-2023 flu season.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: Patients will receive up to 3 text messages reminding them about the importance of influenza vaccination during the 2022-2023 flu season.
Study: NCT05440435

Intervention type: DIAGNOSTIC_TEST
Intervention: digital radiography (DR)
Description: Patients with bone injury received routine and mobile DR sequential examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: digital radiography (DR)
Description: Patients with bone injury received routine and mobile DR sequential examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: digital radiography (DR)
Description: Patients with bone injury received routine and mobile DR sequential examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: digital radiography (DR)
Description: Patients with bone injury received routine and mobile DR sequential examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: digital radiography (DR)
Description: Patients with bone injury received routine and mobile DR sequential examination.
Study: NCT04688528

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose de-escalation and / or Volume de-escalation
Description: The dose de-escalation and/or volume de-escalation strategy will be individually adapted in function of the draining pattern of sentinel lymph nodes on the contralateral side of the neck.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose de-escalation and / or Volume de-escalation
Description: The dose de-escalation and/or volume de-escalation strategy will be individually adapted in function of the draining pattern of sentinel lymph nodes on the contralateral side of the neck.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose de-escalation and / or Volume de-escalation
Description: The dose de-escalation and/or volume de-escalation strategy will be individually adapted in function of the draining pattern of sentinel lymph nodes on the contralateral side of the neck.
Study: NCT06487338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: Is a form of medicine that applies low-level (low-power) lasers that relieve pain.The effects appear to be limited to a specified set of wavelengths

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shock wave Therapy
Description: is a non-invasive treatment that stimulates the body's natural healing process. It can relieve pain and promote healing of injured tendons, ligaments, and other soft tissues
Study: NCT04639778

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Clinical visits conducted by a multidisciplinary team every year

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Clinical visits are triggered by weight evolution measured by connected balance
Study: NCT05193617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP+Penpulimab+Anlotinib
Description: GP combine with penpulimab and anlotinib neoadjuvant therapy+CCRT+penpulimab adjuvant therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GP+Penpulimab
Description: GP combine with penpulimab neoadjuvant therapy+CCRT+penpulimab adjuvant therapy
Study: NCT04894149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Supervised physiotherapy one hour twice weekly and 20 minutes three times weekly during 14- 17 weeks before surgery during neoadjuvant chemotherapy or chemoradiotherapy and during eight weeks after surgery (sometimes during adjuvant chemotherapy)
Study: NCT06489327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melatonin (Circadin ®) 0.2 mg/kg
Description: Patients will receive oral melatonin at a dose of 0.2 mg/kg as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melatonin (Circadin ®) 0.4 mg/kg
Description: Patients will receive oral melatonin at a dose of 0.4 mg/kg as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: Patients will receive oral placebo as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.
Study: NCT05397067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer specialist (PS) and vouchers
Description: this participants will receive vouchers from PS
Study: NCT06062602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-676
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TAK-676 + Carboplatin
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Carboplatin + Paclitaxel
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Carboplatin + 5-FU
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TAK-676 + Carboplatin + 5-FU
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TAK-676 + Carboplatin + Paclitaxel
Description: Intratumoral microdose injection by the CIVO device.
Study: NCT05417334

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resistive Capicitive Monopolar Radiofrequency
Description: 5 Radiofrequency sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Resistive Capicitive Monopolar Radiofrequency
Description: 5 Radiofrequency sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home
Study: NCT04906109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemlidy Tab
Description: 1T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemlidy Tab
Description: 1T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2803 Tab
Description: 1T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2803 Tab
Description: 1T
Study: NCT05534880

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Binaural beats
Description: Condition 02- will be used binaural beats, since they are referred through studies with the ability to drive neural oscillations in the beat frequency through differential hemispheric synchronization frequencies, it is expected that a neuromodulation and repercussion of the symptomatological reduction of CS.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Binaural beats
Description: Condition 02- will be used binaural beats, since they are referred through studies with the ability to drive neural oscillations in the beat frequency through differential hemispheric synchronization frequencies, it is expected that a neuromodulation and repercussion of the symptomatological reduction of CS.
Study: NCT04861285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RACESTYPTINE Solution with cord
Description: The dentist inserts a non-medicated gingival retraction cord into the sulcus and then impregnates the cord in situ with a few drops of RACESTYPTINE Solution. The impregnated cord is left in place a few minutes and then removed. The gingival sulcus is washed and gently air-dried before taking impression.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RACEGEL with cord
Description: The dentist applies a sufficient amount of RACEGEL directly into the sulcus, following the contour of the prepared tooth, and then inserts a non-medicated gingival retraction cord into the sulcus. The impregnated cord is left in place a few minutes and then removed. The sulcus is washed and gently air-dried before taking impression.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RACEGEL without cord
Description: The dentist applies a sufficient amount of RACEGEL directly into the sulcus, following the contour of the prepared tooth. The gel is left in place a few minutes and then removed. The sulcus is washed and gently air-dried before taking impression.
Study: NCT02312596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRP Concepts Fibrin Bio-Matrix
Description: Application of PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual and Customary Practice
Description: Usual and customary care for non-healing wounds

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual and Customary Practice
Description: Usual and customary care for non-healing wounds